Abstract:Key PointsEpigenetic regulation of gene expression relies on covalent, reversible and sequence-specific modifications of histone proteins that package DNA. Deregulation of this control mechanism can lead to multiple diseases.Acetylation and methylation of lysine and arginine residues are the most abundant modifications of the known histone marks. Histone acetyl marks are written by histone acetyltranferases, read by bromodomain-containing proteins and erased by histone deacetylases.Histone methyl marks are written by protein methyltransferases and read by proteins containing chromodomains, Tudor domains, malignant brain tumour domains, PWWP domains and plant homeodomain (PHD) fingers. Histone methyl marks are erased by lysine demethylases.Domains that write, read or erase histone marks are often grouped within a single gene, and these proteins are often combined within multiprotein complexes that mediate crosstalk between specific marks.When they are mutated, aberrantly expressed or driven by aberrant upstream signals, writers, readers and erasers of histone marks can affect the expression patterns of genes that lead to — or even drive — and maintain disease states. Direct associations have been observed in cancer, neuropsychiatric disorders, inflammation and metabolic diseases.Several histone deacetylase inhibitors have reached the clinic and two are approved in oncology. Small-molecule antagonists of bromodomain-containing proteins have demonstrated efficacy in animal models of cancer and inflammation. The chemical tractability of histone acetyltransferases, however, remains unclear.Potent protein methyltransferase inhibitors have been reported, and one compound was active against tumour xenografts in mice. Lysine demethylase inhibitors and antagonists of methyl-lysine readers are at an earlier development stage.

Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs

Targeting cancer epigenetic pathways with small-molecule compounds: Therapeutic efficacy and combination therapies

Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials

Epigenetic Modulators as Therapeutic Agents in Cancer

DNA Methyltransferases: Emerging Targets for the Discovery of Inhibitors As Potent Anticancer Drugs

Epigenetic therapies targeting histone lysine methylation: complex mechanisms and clinical challenges

Targeting Epigenetic Regulatory Enzymes for Cancer Therapeutics: Novel Small-Molecule Epidrug Development

The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy

Novel Insights into Histone Lysine Methyltransferases in Cancer Therapy: from Epigenetic Regulation to Selective Drugs

DNA methyltransferase inhibitors: an updated patent review (2012-2015)

Small molecules targeting selected histone methyltransferases (HMTs) for cancer treatment: Current progress and novel strategies

Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy

DNA methyltransferase inhibitors in cancer: From pharmacology to translational studies

Epigenetic protein families: a new frontier for drug discovery

Deciphering the interplay of histone post-translational modifications in cancer: Co-targeting histone modulators for precision therapy

Emerging therapeutic strategies in cancer therapy by HDAC inhibition as the chemotherapeutic potent and epigenetic regulator

Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA

Epigenetics-targeted drugs: current paradigms and future challenges

Progress Toward Epigenetic Targeted Therapies for Childhood Cancer

Targeting Histone Methylation for Colorectal Cancer

Epigenetic Regulation in Cancer Therapy: from Mechanisms to Clinical Advances